Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $27.6800 (-1.07%) ($27.2100 - $28.0200) on Thu. Jun. 7, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.04% (three month average) | RSI | 12 | Latest Price | $27.6800(-1.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.7% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.7% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) IBB(20%) XOP(18%) IWO(17%) QQQ(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.52% in a week (0% probabilities). VIXM(-11%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.52% (StdDev 3.04%) | Hourly BBV | 0 () | Intraday Trend | -1% | | | |
|
1 - 5 Day Possible Target | $18.36(-33.67%) | Resistance Level | $29.68 | 5 Day Moving Average | $28.02(-1.21%) | 10 Day Moving Average | $28.41(-2.57%) | 20 Day Moving Average | $29.68(-6.74%) | To recent high | -15.3% | To recent low | 22.4% | Market Cap | $783m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |